Medi-Caps Q1 FY27: net loss of Rs 223 lakh; CFO and Director appointed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medi-Caps board approved Q1 FY27 results on 06 Aug 2026. Consolidated revenue was Rs 278.69 lakh with net loss of Rs 223.29 lakh. Standalone revenue was Rs 10.49 lakh with loss of Rs 58.96 lakh. Pharma segment loss was Rs 164.33 lakh. Subsidiary Medgel reported Rs 223.30 lakh loss. Clean auditor review. Akshit Garg is new CFO, Saloni Garg is new Whole-Time Director, CMD Alok K Garg re-appointed for 3 years. AGM on 22 September via video conferencing.
Consolidated net loss narrowed YoY but remains negative. Pharma segment and Medgel subsidiary continue to drag profitability. CFO and Director changes effective from 07 August.